316 related articles for article (PubMed ID: 25025755)
21. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Nakamae H; Shibayama H; Kurokawa M; Fukuda T; Nakaseko C; Kanda Y; Nagai T; Ohnishi K; Maeda Y; Matsuda A; Amagasaki T; Yanada M
Int J Hematol; 2011 May; 93(5):624-632. PubMed ID: 21523338
[TBL] [Abstract][Full Text] [Related]
22. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
23. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD
Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Cortes JE; Lipton JH; Miller CB; Busque L; Akard LP; Pinilla-Ibarz J; Keir C; Warsi G; Lin FP; Mauro MJ
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):286-96. PubMed ID: 26993758
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
26. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
27. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
Hazarika M; Jiang X; Liu Q; Lee SL; Ramchandani R; Garnett C; Orr MS; Sridhara R; Booth B; Leighton JK; Timmer W; Harapanhalli R; Dagher R; Justice R; Pazdur R
Clin Cancer Res; 2008 Sep; 14(17):5325-31. PubMed ID: 18765523
[TBL] [Abstract][Full Text] [Related]
28. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
Koren-Michowitz M; le Coutre P; Duyster J; Scheid C; Panayiotidis P; Prejzner W; Rowe JM; Schwarz M; Goldschmidt N; Nagler A
Cancer; 2010 Oct; 116(19):4564-72. PubMed ID: 20572041
[TBL] [Abstract][Full Text] [Related]
29. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
30. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
31. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
Nicolini FE; Masszi T; Shen Z; Gallagher NJ; Jootar S; Powell BL; Dorlhiac-Llacer PE; Zheng M; Szczudlo T; Turkina A
Leuk Lymphoma; 2012 May; 53(5):907-14. PubMed ID: 22023530
[TBL] [Abstract][Full Text] [Related]
32. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
33. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
34. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
[TBL] [Abstract][Full Text] [Related]
35. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
Nakamae H; Fukuda T; Nakaseko C; Kanda Y; Ohmine K; Ono T; Matsumura I; Matsuda A; Aoki M; Ito K; Shibayama H
Int J Hematol; 2018 Mar; 107(3):327-336. PubMed ID: 29076005
[TBL] [Abstract][Full Text] [Related]
36. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z
Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406
[TBL] [Abstract][Full Text] [Related]
37. [The clinical analysis of frontline nilotinib vs imatinib therapies for newly diagnosed chronic myeloid leukemia in chronic phase].
Yin H; Chen LF; Cui JK; Xiong YY; You Y; Zou P; Li WM
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):810-815. PubMed ID: 29136709
[No Abstract] [Full Text] [Related]
38. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Wang J; Shen ZX; Saglio G; Jin J; Huang H; Hu Y; Du X; Li J; Meng F; Zhu H; Hu J; Wang J; Hou M; Hertle S; Menssen HD; Ortmann CE; Tribouley C; Yuan Y; Baccarani M; Huang X
Blood; 2015 Apr; 125(18):2771-8. PubMed ID: 25766724
[TBL] [Abstract][Full Text] [Related]
39. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
Signorovitch J; Ayyagari R; Reichmann WM; Wu EQ; Chen L
Cancer Treat Rev; 2014 Mar; 40(2):285-92. PubMed ID: 24112812
[TBL] [Abstract][Full Text] [Related]
40. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Schwarz M; Nogai H; Grille P; Westermann J; Plöckinger U; Braun D; Schweizer U; Arnold R; Dörken B; le Coutre P
Thyroid; 2010 Nov; 20(11):1209-14. PubMed ID: 20929406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
